LQDA Liquidia Corporation

Mentions (42)

• Newszacks.com·4d ago·Negative

  Liquidia Stock Plunges 57% on UTHR Patent Litigation Setback LQDA faces a major setback as a patent ruling threatens Yutrepia's PH-ILD indication and creates uncertainty around its commercial outlook.

  View source ↗
• News247wallst.com·4d ago·Negative

  United Therapeutics Won Its Patent War and Liquidia Collapsed A single court ruling sent one pulmonary hypertension drugmaker soaring and left its rival fighting for survival, but the legal battle over Yutrepia's future is far from settled.

  View source ↗
• News (Marketaux)gurufocus.com·5d ago·Positive

  Liquidia (LQDA) Shares Drop 52% After Delaware Court Patent Ruling On September 30, 2026, Liquidia[+253 characters]

  View source ↗
• Newsbusinesswire.com·5d ago·Positive

  United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the United States District Court for the District of Delaware issued an opinion that finds Liquidia Technologies, Inc. (Liquidia) infringes two claims of United Therapeutics' patent covering the use of inhaled treprostinil to treat pulmonary hypertension

  View source ↗
• News (Marketaux)gurufocus.com·5d ago·Neutral

  Delaware Court Ruling Boosts MannKind (MNKD) Outlook Amid Liquidia Patent Dispute Delaware Court Ruling Boosts MannKind (MNKD) Outlook Amid Liquidia Patent Dispute

  View source ↗
• News (RSS)investing·5d ago·Neutral

  Liquidia shares crater after court rules for United Therapeutics

  View source ↗
• News (RSS)investing·5d ago·Neutral

  Liquidia loses patent infringement case on two claims

  View source ↗
• Newsreuters.com·5d ago·Negative

  Liquidia slumps after US court rules for United Therapeutics in patent fight Liquidia shares plunged nearly 50% on Wednesday after a federal judge ruled that its lung drug infringes key patent held by ​rival United Therapeutics , dealing a major blow to the treatment's ‌commercial outlook.

  View source ↗
• Newsseekingalpha.com·5d ago·Positive

  Liquidia: Bullish On Their Growth Potential Despite YUTREPIA's Legal Tail Risk YUTREPIA's adoption is translating into profits and cash, giving Liquidia an operating foundation for further growth. LQDA is already generating substantial cash flows, even though YUTREPIA's growth phase remains in its early stages. The main risk I believe is worth monitoring is LQDA's ongoing legal battle with UTHR over potential patent infringement.

  View source ↗
• Newszacks.com·5d ago·Positive

  LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now? LQDA's Yutrepia drives rapid growth, while ALKS benefits from a diversified portfolio, Lumryz and a broader pipeline.

  View source ↗
• Newsglobenewswire.com·5d ago·Positive

  …fying the proposed remedy, for the District Court's consideration within one week MORRISVILLE, N.C., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today issued an update regarding the litigation filed by United Therapeutics Corporation (UTHR) in the U.S. District Court for the District of Delaware (the Court) under the Hatch…

  View source ↗
• News (Marketaux)gurufocus.com·7d ago·Positive

  Liquidia Corporation (LQDA) Surges Nearly 8% Amid Sector Gains on September 28, 2026 On September 28, 2026, Liquidia[+311 characters]

  View source ↗
• Newszacks.com·12d ago·Negative

  Can LQDA's Yutrepia Outpace Intensifying PAH Competition? Liquidia's Yutrepia posts rapid sales growth, but intensifying competition from established therapies and emerging drugs could test its momentum.

  View source ↗
• Newszacks.com·24d ago·Negative

  LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now? Liquidia's Yutrepia is gaining traction, but patent litigation, competition, rising costs and heavy product dependence cloud LQDA's outlook.

  View source ↗
• Newszacks.com·25d ago·Negative

  Can a Potential Label Expansion of Yutrepia Boost LQDA's Portfolio? Liquidia's Yutrepia wins FDA Fast Track status for SSc-related Raynaud's, opening a potential new growth avenue for the lead drug.

  View source ↗
• News (RSS)yahoo·32d ago·Neutral

  Liquidia Corporation’s (LQDA) Yutrepia Launch Continues to Outpace the Expectations

  View source ↗
• News (Marketaux)gurufocus.com·32d ago·Neutral

  LQDA Looks 75.0% Undervalued on GF Value™ On September 03, 2026, Liquidia[+313 characters]

  View source ↗
• Newsglobenewswire.com·33d ago·Neutral

  Liquidia to Present Posters at the European Respiratory Society (ERS) 2026 Congress MORRISVILLE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it will present two posters at the European Respiratory Society (ERS) 2026 Congress taking place September 5-9, 2026, in Barcelona, Spain.

  View source ↗
• Newsglobenewswire.com·34d ago·Neutral

  Liquidia Corporation to Participate in Wells Fargo Annual Healthcare Conference MORRISVILLE, N.C., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) today announced that Michael Kaseta, Chief Operating Officer and Chief Financial Officer, and Jason Adair, Chief Business Officer, will provide an update on the company's business in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference in Boston on Tuesday, September 8, 2026 at 8:45 a.m.

  View source ↗
• Newszacks.com·35d ago·Neutral

  Can LQDA's Yutrepia Sustain Growth Amid Fierce PAH Competition? Liquidia's Yutrepia is driving rapid growth, but fierce PAH competition and new pipeline therapies could challenge its momentum.

  View source ↗
• Newszacks.com·35d ago·Negative

  Is the Options Market Predicting a Spike in Liquidia Stock? Investors need to pay close attention to LQDA stock based on the movements in the options market lately.

  View source ↗
• Newsseekingalpha.com·38d ago·Negative

  Liquidia: A Linear Launch Priced For Exponential Growth Liquidia Corporation is rated Sell due to YUTREPIA's decelerating growth and an overextended $6B+ valuation. YUTREPIA's percentage growth is compressing, prescriber acquisition has halved, and launch-era tailwinds are fading. Future growth will require difficult community penetration and overcoming structural headwinds from patient mortality and discontinuation.

  View source ↗
• Newszacks.com·39d ago·Positive

  Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now? Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.

  View source ↗
• Newszacks.com·42d ago·Neutral

  Will LQDA's Differentiated PAH Approach Drive Growth? LQDA's Yutrepia is driving rapid growth, but intensifying PAH competition could test its ability to sustain momentum.

  View source ↗
• Newsgurufocus.com·46d ago·Neutral

  Liquidia Corp (LQDA) Shares Fall 5.8% -- What GF Score of 70 Tells Investors On August 20, 2026, Liquidia Corp (LQDA) shares fell 5.8% to $71.05, continuing a downward trend from its 52-week high of $93.61, while still reflecting a subst

  View source ↗
• Newszacks.com·47d ago·Positive

  Can Yutrepia's Strong Growth Drive Liquidia's PAH Expansion? Liquidia's Yutrepia is gaining traction, with $300.3M in first-half sales and nearly 30% of inhaled-market revenues in Q2.

  View source ↗
• News (RSS)fool·47d ago·Positive

  Liquidia (LQDA) Q2 2026 Earnings Call Transcript YUTREPIA sales hit $170.4 million with 5,000+ patients started on therapy.

  View source ↗
• Newszacks.com·49d ago·Neutral

  LQDA Stock Down Post Q2 Earnings Release: What Should Investors Do Now? Liquidia's Yutrepia is fueling rapid growth, but patent litigation, competition and heavy product dependence weigh on its outlook.

  View source ↗
• News (RSS)yahoo·49d ago·Neutral

  Greenhaven Road Capital: Short Term Gain Realized from Liquidia (LQDA), Investment to Be Revisited

  View source ↗
• Newsfool.com·53d ago·Negative

  Why Liquidia Stock Was Diving This Week The shares had risen by 155% year-to-date prior to earnings. Regardless, its one commercialized drug is doing well by any measure.

  View source ↗
• Newszacks.com·53d ago·Positive

  LQDA Q2 Earnings Top, Strong Yutrepia Sales Fuel Top-Line Growth Yutrepia sales fuel Liquidia's Q2 growth as revenues surge and profitability rises, while the company targets more than $1 billion in 2027 revenues.

  View source ↗
• Newszacks.com·53d ago·Positive

  LQDA Q2 Earnings Call Highlights YUTREPIA and $1B 2027 Revenue Path Liquidia targets more than $1 billion in 2027 net revenues as YUTREPIA gains share and funds a broader inhaled-treprostinil pipeline.

  View source ↗
• News (RSS)seekingalpha·54d ago·Neutral

  Liquidia: YUTREPIA's Launch Opens Upside If Growth Remains And Margins Follow

  View source ↗
• Newsseekingalpha.com·54d ago·Neutral

  Liquidia: YUTREPIA's Launch Opens Upside If Growth Remains And Margins Follow YUTREPIA's commercial launch continues to scale, with Q2 product sales of $170.4 million, up 31% sequentially. Q2 largely resolved the margin concern: product gross margin remained about 93.7% despite fully costed inventory, while operating margin reached roughly 49.8%. The key debate has shifted from profitability to growth. Liquidia now needs about $210 million of quarterly revenue in Q3 and Q4 to reach the current $…

  View source ↗
• News (RSS)yahoo·54d ago·Neutral

  Liquidia Corporation Q2 2026 Earnings Call Summary

  View source ↗
• News (RSS)investing·54d ago·Neutral

  Liquidia Q2 2026 slides: YUTREPIA sales surge 31%, 10 studies underway

  View source ↗
• Newsseekingalpha.com·54d ago·Positive

  Liquidia Corporation (LQDA) Q2 2026 Earnings Call Transcript Liquidia Corporation (LQDA) Q2 2026 Earnings Call Transcript

  View source ↗
• Newsmarketbeat.com·54d ago·Neutral

  Liquidia Q2 Earnings Call Highlights Liquidia NASDAQ: LQDA reported second-quarter 2026 results marked by continued growth for its inhaled treprostinil product YUTREPIA, increased profitability and expanding investment in its clinical pipeline.

  View source ↗
• Newszacks.com·54d ago·Neutral

  Liquidia Corporation (LQDA) Q2 Earnings and Revenues Beat Estimates Liquidia Corporation (LQDA) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.7 per share. This compares to a loss of $0.49 per share a year ago.

  View source ↗
• Newsglobenewswire.com·55d ago·Neutral

  Liquidia Corporation Reports Second Quarter 2026 Financial Results YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 Approximately 5,900 unique patient prescriptions and more than 5,000 patients treated between launch in June 2025 and July 31, 2026 Recorded fourth consecutive quarter of increasing profitability, with net income of $74.7 million, adjusted EBITDA of $96.3 million and an

  View source ↗
• News (RSS)seekingalpha·55d ago·Neutral

  Liquidia Q2 2026 Earnings Preview

  View source ↗
• Newszacks.com·56d ago·Neutral

  3 Low-Beta Stocks to Minimize Portfolio Risk: LQDA, PBF & FET Liquidia, PBF Energy and Forum Energy Technologies pair low beta with positive momentum and growth drivers amid market volatility.

  View source ↗